Boffetta P
International Agency for Research on Cancer, Lyon, France.
Toxicol Lett. 1995 May;77(1-3):235-8. doi: 10.1016/0378-4274(95)03301-7.
This article addresses some methodological aspects of the application of biomarkers of exposure, effect and susceptibility to cancer epidemiology. The application of biomarkers to cancer epidemiology should enhance the validity of exposure and outcome measurement, and strengthen the statistical association between exposure and diseases, thus reducing the possibility of random and systematic error. However, the use of biomarkers provides in turn new opportunities for bias and confounding. Small sample size is a limitation of many molecular epidemiology studies. Three major types of bias are recognized: selection bias, information bias (measurement error), and confounding. An important aspect of confounding is that biomarkers can be seen both as exposure and outcome. A second aspect of confounding lies in the role of the biological marker in the causal pathway between exposure and disease. Molecular epidemiology offers better opportunity for the elucidation of interactions between genetic and environmental factors. Genetic susceptibility studies should demonstrate the highest disease risk for exposed susceptible groups and the lowest risk for non-susceptible unexposed groups.
本文探讨了暴露、效应和易感性生物标志物在癌症流行病学应用中的一些方法学问题。生物标志物在癌症流行病学中的应用应提高暴露和结局测量的有效性,并加强暴露与疾病之间的统计关联,从而减少随机误差和系统误差的可能性。然而,生物标志物的使用反过来也为偏倚和混杂提供了新的机会。小样本量是许多分子流行病学研究的一个局限性。公认的三种主要偏倚类型为:选择偏倚、信息偏倚(测量误差)和混杂。混杂的一个重要方面是生物标志物既可以被视为暴露因素,也可以被视为结局。混杂的另一个方面在于生物标志物在暴露与疾病之间因果途径中的作用。分子流行病学为阐明遗传和环境因素之间的相互作用提供了更好的机会。遗传易感性研究应表明,暴露的易感人群疾病风险最高,未暴露的非易感人群风险最低。